|Bid||6,464.00 x 0|
|Ask||6,466.00 x 0|
|Day's Range||6,394.00 - 6,466.89|
|52 Week Range||5,312.00 - 6,634.00|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||34.03|
|Forward Dividend & Yield||2.15 (3.37%)|
|1y Target Est||N/A|
IMFINZI is the only immunotherapy approved to treat patients in this curative-intent setting following chemoradiation therapy
Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo
FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58
Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo
AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.
A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Conference, provides long-term efficacy and safety data for FASENRA from the one-year Phase III SIROCCO and CALIMA exacerbation trials, the one-year Phase III BORA extension trial and the 28-week Phase III ZONDA OCS-sparing trial.
ProPhotonix Announces Results of AGM and Director / PDMR Shareholdings SALEM, NEW HAMPSHIRE / ACCESSWIRE / May 16, 2019 / ProPhotonix Limited (OTC: STKR and London Stock Exchange - AIM: PPIX), a high technology ...
Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes
AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back campaign, focused on ensuring complete biomarker testing becomes standard of care at every late-stage lung cancer diagnosis. The Test It Back site includes a series of inspiring videos featuring Day and his mother, Dening, whose decision to get mutation testing of her Stage IV non-small cell lung cancer last year informed her treatment decisions.
The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards. The awards – a partnership between AstraZeneca and Scientific American Custom Media – includes nominations submitted by organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. “There is so much progress happening in cancer care, but it takes a village to make real change,” expressed Olivier Nataf, Head of US Oncology, AstraZeneca.
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib.
FARXIGA reduced major adverse cardiovascular events by 16% in patients who had a prior heart attack
First sub-analyses from Phase III DECLARE-TIMI 58 trial selected for late-breaking clinical trial and oral presentations
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...
Updated label confirms the well-established efficacy and safety profile for FARXIGA and XIGDUO XR
Phase III POLO Trial Met Primary Endpoint of Progression-Free Survival
BRILINTA reduced cardiovascular events in these patients with no prior heart attack or stroke
SAN DIEGO , Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.S.A. Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation, is a California based research, development and clinical ...
PRESS RELEASE Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics ...
Teva Pharmaceutical Industries’ stock jumped 3.79% Wednesday, to close the day at $19.46. The stock recorded a trading volume of 10,428,002 shares, which was below its three months average volume of 11,332,324 shares. In the last year, Teva Pharmaceutical Industries’ shares have traded in a range of 14.59 - 25.96.
TSE: 4565), announces it has been notified today by its strategic alliance partner AstraZeneca (AZN.L) that it has reached a clinical development milestone with its partnered next generation immuno-oncology candidate AZD4635, triggering a US$15 million payment from AstraZeneca. AZD4635 is a potent and selective, orally available, small molecule adenosine 2A receptor antagonist discovered by the Company and exclusively licensed to AstraZeneca globally in 2015.
AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoint for the treatment of patients with anemia in chronic kidney disease (CKD) that are either non-dialysis-dependent (NDD) or dialysis-dependent (DD), respectively. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and a potential first-in-class new medicine to treat anemia in CKD being jointly developed and commercialized by AstraZeneca and FibroGen, Inc.